

COVID-19 Vaccine Workplace Programme Considerations



Dr. Azwi Takalani
Public Health Medicine Specialist
Safety Physician on Sisonke: Open Label Trial
04 March 2021

MANJURUL/GETTY IMAGES

Conflicts to declare

 Safety physician and Medical monitor in ongoing COVID-19 and HIV vaccine trials. Some trials are sponsored by industry.

Outline

Preparation Phase

- National Roll out Plan: Work based vaccination programmes
- Optimising COVID-19 vaccine coverage in the workplace

Operational Phase

- Vaccine Scheduling
- Vaccine storage & distribution
- Adverse Event Following Immunisation Reporting

Preparation Phase

PHASED APPROACH FOR VACCINE INTRODUCTION

Phase I

Front line health care workers (HCW)

Target population: 1,250,000

Phase II

Essential workers

Target population: 2,500,000

Persons in congregate settings

Target population: 1,100,000

Persons >60 years

Target population: 5,000,000

Persons >18 years with co-

morbidities

Target population: 8,000,000

Phase III

Other persons >18 years

Target population: 22,500,000







PHASE 2 AND 3: HIGH RISK PRIORITY GROUPS AND GENERAL PUBLIC SERVICE DELIVERY PLATFORMS



Public facility vaccination: PHC

Suitable in rural settings for community access



Vaccination Centres: Remote or facility based vaccination centres e.g. community pharmacies, GPs or NGOs – Suitable in urban settings for community access



Outreach vaccination programme: Service provided via mobile clinics Suitable for congregated settings e.g. old age homes



Work-based vaccination programme: Suitable for Essential workers e.g. mining sector , industry and departments





Optimising COVID-19 vaccine coverage in the workplace



Mandatory Vaccination Policies in the Workplace?





Bill of Rights: Freedom & Security of the Person



National Health Act – Informed Consent




Occupational Health and Safety Act – Health & Safety at Work











Employee Capacitation: Informed Decision Making



Vaccine Hesitancy Immunity

Vaccine Science

How vaccines work

Vaccine Development

Vaccine Efficacy

Per vaccine candidate

Continuance of NPI



Safety Profiles

Common reactogenicity profile

Contextualise serious adverse events

Regulatory Processes

Development and licensing processes

Managing Exemptions

- Medical Exemptions
 - Severe allergic reactions to vaccine constituents
- Religious Exemptions
 - Explore grounds is employee willing
- Choice
- Document vaccine offer; employee decision & contingency plan (if applicable)

Operational Phase

Vaccine Scheduling

- Vaccine scheduling balance of optimising vaccine coverage vs operational needs
 - Staggered approach
 - Job category & shift mixing
- Reactogenicity profile
 - Days off post vaccination e.g. vaccinee develops fever
 - Two dose regimens

Vaccine storage & distribution

Product	Design	Adjuvant	Cold chain
Moderna mRNA-1273	mRNA	-	- 20 degreesC
AstraZeneca AZD1222	Chimp adenovirus vector	-	2 to 8 degreesC
Janssen Ad26.COV2.S	Human adenovirus-26 vector	-	2 to 8 degreesC
Novavax SARS- CoV-2 rS	Protein Subunit Nanoparticle	Matrix-M™	2 to 8 degreesC
Pfizer	mRNA	-	- 70 degreesC

- Reliable refrigerators/freezers
- Temperature monitoring devices
- Temperature excursion management protocols
- Vaccine inventory management systems
- Transportation

Adverse Event Following Immunisation Reporting



ALL VACCINES including COVID-19

CASE REPORTING FORM (CRF) FOR ADVERSE EVENTS FOLLOWING IMMUNISATION (AEFI)



Country - Province - District - Year - Case no

Today's date: DD/MM/YYYY

All fields in this form are mandatory, unless indicated 'if applicable'. Provide the requested information or tick the appropriate box.

Date received	Level	Signature
	Private	
	District	
	Province	
	National EPI	
	National SAHPRA	
(For Office use only)		

SECTION A: IDENTIFYING INFORMATION

NOTE: In maternal vaccination, if mother and baby / more than one baby are affected, complete separate form for each affected individual



Align reporting with AEFI requirements embedded in Expanded Programme on Immunisation



Currently paper based, electronic tool being developed

Thank you